All studies
Phase 3RecruitingInterventionalNCT07359846

A Study to Investigate GB-0895 Adjunctive Therapy in Adults and Adolescents With Severe Uncontrolled Asthma (SOLAIRIA-2)

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of GB-0895 Adjunctive Therapy in Adults and Adolescents With Severe Uncontrolled Asthma

  • Severe Asthma
I want to take partRefer a patient2 sites in India · 158 worldwide

At a glance

Phase
Phase 3
Study type
Interventional
Sponsor
Generate Biomedicines
Enrolment target
786
Started
20 January 2026
Main results due (estimated)
January 2029
Study ends (estimated)
January 2029
Allocation
Randomized
Design
Parallel
Purpose
Treatment
Masking
Triple (participant, care provider, investigator)
Sites
158 · 2 in India
First posted
22 January 2026
Registry updated
3 November 2026

Can you take part?

  • Ages 12 years to 80 years.
  • Open to any sex.
  • You need the condition being studied. Healthy volunteers are not accepted.

Age groups: child, adult, older adult.

These are the headline rules. Every study has a longer list, and whether you are eligible is decided by the research team at the site, never by this page.

Read the full eligibility criteria
1. Adults and adolescents ≥ 12 and ≤ 80 years of age.
2. Documented diagnosis of asthma for \> 12 months.
3. Subjects must be on medium to high dose ICS for ≥ 12 months before Screening Visit 1 plus at least 1 additional asthma controller (e.g., LABA, LAMA) ≥ 3 months before Screening Visit 1 with no change in ICS or controller(s) for at least three months.
4. Subjects must have a well-documented history of at least two asthma exacerbations requiring systemic corticosteroid treatment despite the use of medium-to-high dose ICS in the past 12 months before Screening Visit 1.
5. Adults ≥ 18 years of age at Screening Visit 1, a pre-BD FEV1 \<80% predicted at Screening Visit 1.
6. Adolescents 12 to \< 18 years of age at Screening Visit 1: A pre-BD FEV1 \< 90% predicted OR, FEV1:Forced Vital Capacity (FVC) ratio \< 0.80.
7. Positive BD responsiveness test: Increase of at least 12% and 200 mL in FEV1 between 15 and 60 minutes after the administration of a short-acting β2-agonist (SABA) at least once during the screening period.
8. ACQ-6 score ≥ 1.5 at the Screening Visit.
9. Weight ≥40 kg at the Screening Visit 1

Exclusion Criteria:

1. Subjects who experience a clinically significant asthma exacerbation within 12 weeks before the Screening Visit or during the run-in period and require a change in asthma maintenance therapy.
2. Other concurrent respiratory disease other than asthma, including (but not limited to) current infection, bronchiectasis, pulmonary fibrosis, bronchopulmonary aspergillosis, tuberculosis, diagnosis of chronic pulmonary disease (including but not limited to emphysema and/or chronic bronchitis), or a history of lung cancer.
3. Eosinophilic disease (e.g., eosinophilic granulomatosis with polyangiitis).
4. Any cardiovascular, gastrointestinal, hepatic, renal, neurological, musculoskeletal, infectious, endocrine, metabolic, hematological, psychiatric, or major physical impairment that is not stable in the opinion of the Investigator and could affect subject safety, influence study findings or interpretation, or impede completion of the study.
5. Clinically significant infection that is unresolved and requires systemic antibiotic, antifungal, antiparasitic, or antiviral medications preceding enrollment.
6. A current malignancy or previous history of cancer within 5 years before screening.
7. Clinically significant infection that is not resolved before study enrollment.
8. Subjects with a known, pre-existing helminth parasitic infestation within 6 months before Screening Visit 1 that has not been successfully treated with, or has failed to respond to, standard of care therapy.
9. Current smokers or subjects with a smoking history ≥10 pack-years, and subjects using vaping products, including electronic cigarettes.
10. Former smokers with a smoking history of \<10 pack-years and users of vaping/e-cigarette products must have stopped for at least 6 months before Screening Visit 1 to be eligible.
11. Hepatitis B, C, or HIV.
12. Major surgery within 8 weeks before Screening Visit 1 or planned surgical procedures requiring general anesthesia or inpatient status for \>1 day during the study.
13. Use of any anti-IL-5 therapy (e.g., mepolizumab, reslizumab, benralizumab, depemokimab) or other monoclonal antibodies used for asthma within 4 months or 5 half-lives.
14. Previous use of tezepelumab within 12 months before Screening Visit 1 is excluded. Previous tezepelumab use is exclusionary regardless of 12-month washout if discontinuation was due to safety (intolerance) or treatment failure (lack of benefit). Prior use (at any time) of any other anti-TSLP or anti-TSLP receptor biologics is excluded.
15. Treatment with systemic immunosuppressive/immunomodulating drugs (e.g., methotrexate, cyclosporine) within 12 weeks prior to randomization.
16. Receipt of an investigational biologic within 4 months or 5 half-lives (whichever is longer), OR receipt of an investigational non-biologic within 30 days or 5 half-lives (whichever is longer) before Screening Visit 1.
17. Known history of sensitivity to any component of the study treatment formulation.
18. History of life-threatening anaphylaxis following any biologic therapy.
19. Concurrent enrollment in another clinical study involving investigational product (IP).
20. Subject has been randomized in the current study or previous GB-0895 studies.
21. Any clinically meaningful abnormal finding in physical examination, vital signs, ECG, hematology, serum chemistry, or urinalysis that, in the opinion of the Investigator, may put the subject at risk, influence study results, or impede study completion.
22. Cirrhosis (with or without hepatic dysfunction) or other active or clinically significant liver disease.
23. Receipt of immunoglobulin or blood products within 30 days before Screening Visit 1.
24. Receipt of live attenuated vaccines within 30 days before randomization and during the study, including the follow-up period.
25. Receipt of the T2 cytokine inhibitor suplatast tosilate within 15 days before Screening Visit 1.
26. Subjects treated with bronchial thermoplasty in the last 12 months before Screening Visit 1.
27. Unwillingness or inability to follow study procedures, including poor adherence to asthma controller medications, in the opinion of the Investigator.
28. Women who are pregnant, lactating, or planning to become pregnant during the study.
29. History (or suspected history) of alcohol misuse or substance abuse within 2 years before Screening Visit 1.

What this study is about

In the sponsor’s own words, from the registry.

The objective of this study is to assess the potential for GB-0895 to improve the health of adolescents and adults with severe asthma that is uncontrolled by inhaled corticosteroids (ICS) and conventional asthma controllers.

Additional information is available at www.SOLAIRIA.com.

Read the detailed description

This is a global, multicenter, randomized, double-blind, placebo-controlled Phase 3 study to evaluate the efficacy and safety of GB-0895 adjunctive therapy in adults and adolescents with severe uncontrolled asthma with an optional open-label extension (OLE). The trial is designed to administer GB-0895 an investigational drug or placebo, subcutaneously every 6 months.

The study is divided into several phases as described below:

* Screening/Run-In (Weeks -5 to 0) * Treatment (Weeks 0 to 52) * Follow-up (Weeks 52 to 90) or optional open-label extension (OLE) (Weeks 52 to 142, OLE includes GB-0895 treatment on Week 52 and Week 78)

Keywords: Asthma · Severe Asthma · Uncontrolled Asthma · Adolescent Asthma

What participants receive

  • Experimental

    GB-0895

    GB-0895 Subcutaneous (SC) injection

    Drug: GB-0895

  • Placebo comparator

    Placebo

    Placebo Subcutaneous (SC) injection

    Drug: Placebo

Interventions

  • GB-0895Drug

    Study Drug

  • PlaceboDrug

What the study measures

Primary outcomes

  1. To evaluate the annualized asthma exacerbation rate (AAER) in adult and adolescent subjects with severe uncontrolled asthma.

    The annual exacerbation rate is based on clinically significant (CS) exacerbations reported by the investigator in the electronic case (eCRF) over 52 weeks for subjects on GB-0895 as compared to placebo.

    Time frame: From Day 1 (randomization) to Week 52

Secondary outcomes

  1. To evaluate the annualized asthma exacerbation rate (AAER) in adult and adolescent subjects with severe uncontrolled asthma and baseline eosinophils (EOS) < 300 cells/µL.

    The annual exacerbation rate is based on CS exacerbations reported by the investigator in the eCRF over 52 weeks for subjects with baseline EOS \< 300 cells/ µL on GB-0895 as compared to placebo.

    Time frame: From Day 1 (randomization) to Week 52

  2. Change from baseline in pre-bronchodilator (BD) forced expiratory volume in 1 second (FEV1)

    The change from baseline in pre-BD FEV1 for subjects on GB-0895 as compared to placebo at week 52. FEV1 is defined as the volume of air exhaled from the lungs in the first second of a forced expiration.

    Time frame: From Day 1 (randomization) to Study Week 52

  3. Change from baseline in Asthma Quality of Life Questionnaire AQLQ(S)12+ score

    The change from baseline on AQLQ(S)12+ score for subjects on GB-0895 as compared to placebo at week 52. The AQLQ(S)12+ is a 32-question assessment with questions related to symptoms, activity limitations, emotional function, and environmental stimuli. Questions are scored on a 7-point scale, which ranges from 7 (no impairment) to 1 (severe impairment). The overall score is calculated as the mean to all questions.

    Time frame: From Day 1 (randomization) to Week 52

  4. Change from baseline in Asthma Control Questionnaire (ACQ-6) score

    The change from baseline on ACQ-6 score for subjects on GB-0895 as compared to placebo at week 52. The ACQ-6 is a 6-question questionnaire that assesses asthma symptoms (e.g., activity limitation, shortness of breath, wheezing etc.). Questions are scored on a 6-point scale, where 0 corresponds to totally controlled asthma and 6 corresponds to severely uncontrolled asthma.

    Time frame: From Day 1 (randomization) to Week 52

  5. Time to first asthma exacerbation from randomization

    After subjects complete the screening period and are randomized to either GB-0895 or placebo, the time it takes until the first clinically significant asthma exacerbation to occur.

    Time frame: From Day 1 (randomization) to Week 52

  6. Change from baseline in weekly mean daily Asthma Daytime Symptom Diary (ADSD)

    The change from baseline on weekly mean daily ADSD score for subjects on GB-0895 as compared to placebo at week 52. The ADSD is an 8-question diary that assesses asthma daytime symptoms that the subjects will fill out at night before bed. The ADSD daily score is calculated by averaging the 8 daily score and a mean of 7-day ADSD score is calculated by averaging of the seven daily score.

    Time frame: From Day 1 (randomization) to Week 52

  7. Change from baseline in weekly mean daily Asthma Nighttime Symptom (ANSD)

    The change from baseline on daily ANSD score for subjects on GB-0895 as compared to placebo at week 52. ANSD is an eight-question diary that assesses asthma symptoms that the subjects will fill out in the morning upon waking. The ANSD score is calculated by averaging the 8 daily score and a mean of 7-day ANSD score is calculated by averaging of the seven daily score.

    Time frame: From Day 1 (randomization) to Week 52

  8. Change from baseline in St. George's Respiratory Questionnaire (SGRQ) total score

    The change from baseline on SGRQ score for subjects on GB-0895 as compared to placebo at week 52. The SGRQ is a 50-item questionnaire designed to measure health status. Questions are scored on a range of 0 to 100, with a lower score indicating a better quality of life

    Time frame: From Day 1 (randomization) to Week 52

  9. Change from baseline in the 5-Level EuroQol 5 dimensions questionnaire (EQ-5D-5L) score

    The change from baseline on EQ-5D-5L score for subjects on GB-0895 as compared to placebo at week 52. The EQ-5D-5L questionnaire includes a visual analogue scale (VAS) that allows subjects to rate current health status on a 0-100 scale, with 0 being the worst imaginable health state.

    Time frame: From Day 1 (randomization) to Week 52

  10. PGI-S response at Week 52

    The Patient Global Impression of Asthma Severity (PGI-S) at Week 52 defined as an improvement by 1 or more points on the 0-5 scale. The PGI-S questionnaire asks the subjects to rate the overall severity of their asthma symptoms of the past 7 days with response options of: 1= no asthma symptoms, 2= mild, 3= moderate, 4= severe, and 5= worst possible asthma symptoms.

    Time frame: From Day 1 (randomization) to Week 52

  11. ACQ-6 response at Week 52

    The Asthma Control Questionnaire-6 (ACQ-6) at Week 52 defined as an improvement in score of 0.5 or more.

    Time frame: From Day 1 (randomization) to Week 52

  12. AQLQ(S)12+ response at Week 52

    The Asthma Quality of Life Questionnaire for 12 Year Old and Older at week 52 defined as an improvement in score of 0.5 or more.

    Time frame: From Day 1 (randomization) to Week 52

  13. SGRQ response at Week 52

    The St. George's Respiratory Questionnaire at week 52 defined as achieving ≥ 4-point reduction from baseline.

    Time frame: From Day 1 (randomization) to Week 52

  14. PGI-C responder at Week 52

    The Patient Global Impression of Change (PGI-C) improved response is defined as reporting at least 'moderately better' at week 52. The PGI-C questionnaire asks the subjects to describe the overall change in their asthma since they started taking new medication with response options of: 1= much better, 2= better, 3= a little better, 4= no change, 5= a little worse, 6= worse, and 7= much worse.

    Time frame: From Day 1 (randomization) to Week 52

  15. To evaluate the effect of GB-0895 on asthma exacerbations associated with Emergency Room or Hospitalization Visits

    The time to first clinically significant asthma exacerbation, from randomization, requiring hospitalization or emergency room visit.

    Time frame: From Day 1 (randomization) to Week 52

  16. To evaluate the effect of GB-0895 on annualized asthma exacerbation rate (AAER) associated with Emergency Room or Hospitalization Visits

    The AAER associated with clinically significant exacerbations associated with hospital or emergency room visits over 52 weeks.

    Time frame: From Day 1 (randomization) to Week 52

  17. Adverse Events (AEs) and Serious Adverse Events (SAEs)

    To investigate the incidence, severity, and relationship to GB-0895 of AEs and SAEs throughout the study as reported by the Investigator in the electronic case report forms (eCRFs).

    Time frame: From Day 1 (randomization) to Week 52

  18. Clinical Laboratory Evaluations

    The absolute values and changes from baseline of clinical laboratory evaluations over time.

    Time frame: From Day 1 (randomization) to Week 52

  19. Vital Signs

    The absolute values and changes from baseline of vital signs over time.

    Time frame: From Day 1 (randomization) to Week 52

  20. ECGs (electrocardiogram)

    The absolute values and changes from baseline of ECGs over time.

    Time frame: From Day 1 (randomization) to Week 52

  21. Immunogenicity of GB-0895

    The measurement of anti-drug antibodies (ADA) responses throughout the course of the study. for subjects on GB-0895 as compared to placebo at week 52.

    Time frame: From Day 1 (randomization) to Week 52

Who is running it

Lead sponsor
Generate Biomedicines
Sponsor type
Industry
Responsible party
The sponsor
Organisation
Generate Biomedicines
Data monitoring committee
Yes
US FDA-regulated drug
Yes
US FDA-regulated device
No
Sponsor's study ID
GB-0895-302 (SOLAIRIA-2)
  • Snodgres

    Study director

    Generate Biomedicines

Study sites(158)

Showing 40 of 158 sites. 158 recruiting, 0 not recruiting and 0 cancelled; 2 in India. Not recruiting covers sites not yet open, finished enrolling, completed or paused; cancelled covers sites withdrawn before opening or stopped for good.

References and data sharing

Participant data shared
No

Source: ClinicalTrials.gov record NCT07359846, status verified December 2025. Trialion does not run this study, is not paid to refer anyone to it, and cannot enrol you. Eligibility is always decided by the research team at the site.

Take part

Interested in this study?

Tell us how to reach you and we will connect you with the study team. Or refer someone you care for, with their permission.

A person reads this, not a bot. We are not doctors, this is not medical advice, and it is not for emergencies.

Not the right study?

Every study recruiting in India, one search away.